Recent Advances in Microfluidic-based Cancer Immunotherapy-on-a-chip Strategies

Overview

Journal Biomicrofluidics

Publisher American Institute of Physics

Specialty Biomedical Engineering

Date 2023 Jan 17

PMID 36647540

Authors

Thi Kim Ngan Ngo

Cheng-Hsiang Kuo

Ting-Yuan Tu

Affiliations

Soon will be listed here.

Abstract

Despite several extraordinary improvements in cancer immunotherapy, its therapeutic effectiveness against many distinct cancer types remains mostly limited and requires further study. Different microfluidic-based cancer immunotherapy-on-a-chip (ITOC) systems have been developed to help researchers replicate the tumor microenvironment and immune system. Numerous microfluidic platforms can potentially be used to perform various on-chip activities related to early clinical cancer immunotherapy processes, such as improving immune checkpoint blockade therapy, studying immune cell dynamics, evaluating cytotoxicity, and creating vaccines or organoid models from patient samples. In this review, we summarize the most recent advancements in the development of various microfluidic-based ITOC devices for cancer treatment niches and present future perspectives on microfluidic devices for immunotherapy research.

Citing Articles

Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.

Maity S, Bhuyan T, Jewell C, Kawakita S, Sharma S, Nguyen H Small. 2024; 21(1):e2405511.

PMID: 39535474 PMC: 11719323. DOI: 10.1002/smll.202405511.

Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy.

Chen D, Xu L, Xuan M, Chu Q, Xue C Clin Transl Med. 2024; 14(9):e1802.

PMID: 39245957 PMC: 11381553. DOI: 10.1002/ctm2.1802.

AI-Assisted Detection of Biomarkers by Sensors and Biosensors for Early Diagnosis and Monitoring.

Wasilewski T, Kamysz W, Gebicki J Biosensors (Basel). 2024; 14(7).

PMID: 39056632 PMC: 11274923. DOI: 10.3390/bios14070356.

Microphysiological systems as models for immunologically 'cold' tumors.

Gaebler D, Hachey S, Hughes C Front Cell Dev Biol. 2024; 12:1389012.

PMID: 38711620 PMC: 11070549. DOI: 10.3389/fcell.2024.1389012.

Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity.

Moon H, Surianarayanan N, Singh T, Han B Biomicrofluidics. 2024; 17(6):061504.

PMID: 38162229 PMC: 10756708. DOI: 10.1063/5.0179444.

References

Al-Samadi A, Poor B, Tuomainen K, Liu V, Hyytiainen A, Suleymanova I . In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients. Exp Cell Res. 2019; 383(2):111508. DOI: 10.1016/j.yexcr.2019.111508. View

Wei S, Duffy C, Allison J . Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018; 8(9):1069-1086. DOI: 10.1158/2159-8290.CD-18-0367. View

Ogasawara M, Miyashita M, Yamagishi Y, Ota S . Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia. Ther Apher Dial. 2022; 26(3):537-547. DOI: 10.1111/1744-9987.13828. View

Aboulkheyr Es H, Zhand S, Thiery J, Warkiani M . Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integr Biol (Camb). 2020; 12(7):188-197. DOI: 10.1093/intbio/zyaa014. View

Giraldo N, Sanchez-Salas R, Peske J, Vano Y, Becht E, Petitprez F . The clinical role of the TME in solid cancer. Br J Cancer. 2018; 120(1):45-53. PMC: 6325164. DOI: 10.1038/s41416-018-0327-z. View

Lee J, Bechstein D, Ooi C, Patel A, Gaster R, Ng E . Magneto-nanosensor platform for probing low-affinity protein-protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction. Nat Commun. 2016; 7:12220. PMC: 4961847. DOI: 10.1038/ncomms12220. View

Qiao H, Chen X, Wang Q, Zhang J, Huang D, Chen E . Tumor localization of oncolytic adenovirus assisted by pH-degradable microgels with JQ1-mediated boosting replication and PD-L1 suppression for enhanced cancer therapy. Biomater Sci. 2020; 8(9):2472-2480. DOI: 10.1039/d0bm00172d. View

Geyer M, Queiroz K . Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening. Front Cell Dev Biol. 2022; 9:761807. PMC: 8733732. DOI: 10.3389/fcell.2021.761807. View

Menz W, Guber A . Microstructure technologies and their potential in medical applications. Minim Invasive Neurosurg. 1994; 37(1):21-7. DOI: 10.1055/s-2008-1053444. View

10.

Du Y, Liu Y, Wang D, Bai H, Wang Z, He X . Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors. J Immunother Cancer. 2022; 10(2). PMC: 8883272. DOI: 10.1136/jitc-2021-003564. View

11.

Giannattasio A, Weil S, Kloess S, Ansari N, Stelzer E, Cerwenka A . Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids. BMC Cancer. 2015; 15:351. PMC: 4422268. DOI: 10.1186/s12885-015-1321-y. View

12.

Kandarian F, Sunga G, Arango-Saenz D, Rossetti M . A Flow Cytometry-Based Cytotoxicity Assay for the Assessment of Human NK Cell Activity. J Vis Exp. 2017; (126). PMC: 5614136. DOI: 10.3791/56191. View

13.

Layer J, Kronmuller M, Quast T, van den Boorn-Konijnenberg D, Effern M, Hinze D . Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology. 2017; 6(6):e1320626. PMC: 5486176. DOI: 10.1080/2162402X.2017.1320626. View

14.

Segaliny A, Li G, Kong L, Ren C, Chen X, Wang J . Functional TCR T cell screening using single-cell droplet microfluidics. Lab Chip. 2018; 18(24):3733-3749. PMC: 6279597. DOI: 10.1039/c8lc00818c. View

15.

Sehgal K, Portell A, Ivanova E, Lizotte P, Mahadevan N, Greene J . Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest. 2020; 131(2). PMC: 7810472. DOI: 10.1172/JCI135038. View

16.

Boussommier-Calleja A, Atiyas Y, Haase K, Headley M, Lewis C, Kamm R . The effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model. Biomaterials. 2018; 198:180-193. PMC: 6123301. DOI: 10.1016/j.biomaterials.2018.03.005. View

17.

Liang S, Xu K, Niu L, Wang X, Liang Y, Zhang M . Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. Onco Targets Ther. 2017; 10:4273-4281. PMC: 5584889. DOI: 10.2147/OTT.S139986. View

18.

Ogiwara Y, Nakagawa M, Nakatani F, Uemura Y, Zhang R, Kudo-Saito C . Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma. Cancer Lett. 2022; 537:215690. DOI: 10.1016/j.canlet.2022.215690. View

19.

Reyes M, Vickers D, Billman K, Eisenhaure T, Hoover P, Browne E . Multiplexed enrichment and genomic profiling of peripheral blood cells reveal subset-specific immune signatures. Sci Adv. 2019; 5(1):eaau9223. PMC: 6357748. DOI: 10.1126/sciadv.aau9223. View

20.

Gopal S, Kwon S, Ku B, Lee D, Kim J, Dordick J . 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. Commun Biol. 2021; 4(1):893. PMC: 8295284. DOI: 10.1038/s42003-021-02417-2. View